➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Johnson and Johnson
McKinsey
Mallinckrodt

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 6,440,445

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,440,445
Title: Methods and compounds for treatment of abnormal uterine bleeding
Abstract:The invention provides methods for treating abnormal uterine bleeding via application of compounds that block uterine stromal cell response to angiogenic growth factors by interfering with the growth factors themselves, by blocking receptors in the uterine epithelial or stromal cells to those growth factors, and/or by inhibiting other receptors to those growth factors. The compounds include interferons, particularly type I interferons, pirfenidone, heparin, heparin-like polyaromatic anionic compounds, heparin-sulfate-based compounds, secreted or soluble FGF receptors, and/or RGD-peptide. The angiogenic growth factors to which response is blocked include basic fibroblast growth factor (bFGF), FGF receptors (FGFR), acidic fibroblast growth factor (aFGF), transforming growth factor .beta. (TGF-.beta.), platelet-derived growth factor (PDGF), heparin binding epidermal growth factor (HBEGF), vascular endothelial growth factor (VEGF), parathyroid hormone-related protein (PTHrP) and/or prolactin. The methods contemplate introducing the aforementioned response-blocking compounds into the body of a patient either systemically, e.g., via injection or implant, or locally to the uterus, e.g., via medicated intrauterine devices, foams and the like. The invention also provides methods for female contraception comprising administering the aforementioned response-blocking compounds, along with progestin or a progestin-only contraceptive, to inhibit pregancy while reducing bleeding otherwise associated with such contraceptives.
Inventor(s): Nowak; Romana A. (West Roxbury, MA), Stewart; Elizabeth A. (Cambridge, MA)
Assignee: Brigham & Women\'s Hospital (Boston, MA)
Application Number:09/011,969
Patent Claims:see list of patent claims

Details for Patent 6,440,445

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Brigham & Women\'s Hospital (Boston, MA) 2016-09-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Brigham & Women\'s Hospital (Boston, MA) 2016-09-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Brigham & Women\'s Hospital (Boston, MA) 2016-09-30 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Brigham & Women\'s Hospital (Boston, MA) 2016-09-30 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKesson
Colorcon
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.